BAXTER INTERNATIONAL INC
BAXNYSE · SIC 3841
$22.61
↓ -3.2%Jul 17 close · end-of-day
Price
1Y↓ -19.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$11.6B
Enterprise Value
$10.5B
P/E
—
P/S
1.0
P/B
1.9
EV/EBITDA
15.6
PEG
—
FCF Yield
—
Dividend Yield
1.6%
Revenue (TTM)
$11.3B
Net Income (TTM)
-$1.1B
Free Cash Flow (TTM)
—
Gross Margin
30.1%
Operating Margin
-2.6%
Net Margin
-9.7%
ROE
-18.2%
ROIC
-4.9%
Debt / Equity
0.1
Net Cash
$1.2B
Return 1Y
-18.2%
Company profile
Baxter International Inc. develops and provides a portfolio of healthcare products worldwide. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries.
- CEO
- José E. Almeida
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 60,000
- Headquarters
- Illinois
- Website
- baxter.com
Management & directors
- Teaff JamesPresident, CCS
- Wallace Steven P.President, Adv. Surgery
- Zielinski Anita ASVP, Interim CFO, CAO & Cntrlr
- Grade Joel T.EVP and CFO
- Rasul ReazEVP,Group Pres,Healthcare
- Rosenbloom David S.EVP and General Counsel
- Soriano Maria CeciliaGroup Pres., ITT & Pharma.
- Carlisle CynthiaExecutive Vice President, CHRO
- Hider Andrew P.President and CEO
- Mason Jeanne KEVP, Chief HR Officer
- Borzi James WEVP,Chief Supply Chain Officer
- Sonig AlokEVP,Group President,Pharma
Roles derived from SEC Form 4 filings.
Earnings
Next earnings · estimated2026-07-30
BAX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$2.7B↑ +2.9%
Diluted EPS-$0.03↓ -112.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $11.7B | $12.1B | $10.1B | $10.4B | $10.6B | $11.2B |
| Gross profit | $4.6B | $4.7B | $3.5B | $4.2B | $4.0B | $3.4B |
| Operating income | $1.6B | $1.4B | -$2.8B | $707.0M | $14.0M | -$308.0M |
| Net income | $1.1B | $1.3B | -$2.4B | $2.7B | -$649.0M | -$957.0M |
| Diluted EPS | $2.13 | $2.53 | -$4.83 | $5.23 | -$1.27 | -$1.87 |
| Operating cash flow | $1.9B | $2.2B | $1.2B | $1.7B | $1.0B | $845.0M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | 39.3% | 38.9% | 35.3% | 40.1% | 37.5% | 30.1% |
| Operating margin | 13.8% | 11.1% | -28.3% | 6.8% | 0.1% | -2.7% |
| Net margin | 9.4% | 10.6% | -24.2% | 25.6% | -6.1% | -8.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.7B | $2.7B | $2.8B | $2.6B | $2.8B | $2.8B | $3.0B | $2.7B |
| Gross profit | $1.0B | $1.0B | $959.0M | $861.0M | $991.0M | $950.0M | $577.0M | $891.0M |
| Operating income | $179.0M | $155.0M | -$435.0M | $58.0M | $191.0M | $172.0M | -$729.0M | $66.0M |
| Net income | -$314.0M | $140.0M | -$512.0M | $126.0M | $91.0M | -$46.0M | -$1.1B | -$15.0M |
| Diluted EPS | -$0.61 | $0.27 | -$1.00 | $0.25 | $0.18 | -$0.09 | -$2.21 | -$0.03 |
| Operating cash flow | $115.0M | $253.0M | $488.0M | -$193.0M | $217.0M | $237.0M | $584.0M | $213.0M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | 38.3% | 38.3% | 34.8% | 32.8% | 35.3% | 33.5% | 19.4% | 33.0% |
| Operating margin | 6.6% | 5.7% | -15.8% | 2.2% | 6.8% | 6.1% | -24.5% | 2.4% |
| Net margin | -11.7% | 5.2% | -18.6% | 4.8% | 3.2% | -1.6% | -37.9% | -0.6% |
Company news
Jul 16, 2026
Jul 15, 2026
Jul 9, 2026
Jul 7, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-02 | Teaff James· President, CCS | Tax withholding | 321 | $18.68 | $5,996.28 | filing |
| 2026-06-02 | Wallace Steven P.· President, Adv. Surgery | Tax withholding | 153 | $18.68 | $2,858.04 | filing |
| 2026-06-01 | Zielinski Anita A· SVP, Interim CFO, CAO & Cntrlr | Award | 13,426 | $0.00 | $0.00 | filing |
| 2026-05-05 | SCHLICHTING NANCY M | Award | 12,836 | $0.00 | $0.00 | filing |
| 2026-05-05 | Shafer David Brent | Award | 12,836 | $0.00 | $0.00 | filing |
| 2026-05-05 | McDonnell Michael R. | Award | 12,836 | $0.00 | $0.00 | filing |
| 2026-05-05 | Craig Jeffrey A | Award | 12,836 | $0.00 | $0.00 | filing |
| 2026-05-05 | Ampofo William A. II | Award | 12,836 | $0.00 | $0.00 | filing |
| 2026-05-05 | MORRISON PATRICIA | Award | 12,836 | $0.00 | $0.00 | filing |
| 2026-05-05 | Wilkes David S. | Award | 12,836 | $0.00 | $0.00 | filing |
| 2026-05-05 | Wendell Amy McBride | Award | 12,836 | $0.00 | $0.00 | filing |
| 2026-03-06 | Rasul Reaz· EVP,Group Pres,Healthcare | Tax withholding | 12,674 | $17.69 | $224,203.06 | filing |
| 2026-03-06 | Grade Joel T.· EVP and CFO | Tax withholding | 8,153 | $17.69 | $144,226.57 | filing |
| 2026-03-06 | Rosenbloom David S.· EVP and General Counsel | Tax withholding | 6,620 | $17.69 | $117,107.80 | filing |
| 2026-03-06 | Soriano Maria Cecilia· Group Pres., ITT & Pharma. | Tax withholding | 2,848 | $17.69 | $50,381.12 | filing |
| 2026-03-06 | Zielinski Anita A· SVP, CAO and Controller | Tax withholding | 1,932 | $17.69 | $34,177.08 | filing |
| 2026-03-02 | Soriano Maria Cecilia· Group Pres., ITT & Pharma. | Tax withholding | 1,852 | $19.69 | $36,465.88 | filing |
| 2026-03-02 | Rasul Reaz· EVP,Group Pres,Healthcare | Tax withholding | 1,614 | $19.69 | $31,779.66 | filing |
| 2026-03-02 | Rosenbloom David S.· EVP and General Counsel | Tax withholding | 1,336 | $19.69 | $26,305.84 | filing |
| 2026-02-27 | Grade Joel T.· EVP and CFO | Award | 42,735 | $0.00 | $0.00 | filing |
| 2026-02-27 | Carlisle Cynthia· Executive Vice President, CHRO | Award | 17,806 | $0.00 | $0.00 | filing |
| 2026-02-27 | Hider Andrew P.· President and CEO | Award | 201,804 | $0.00 | $0.00 | filing |
| 2026-02-27 | Carlisle Cynthia· Executive Vice President, CHRO | Award | 11,871 | $0.00 | $0.00 | filing |
| 2026-02-27 | Soriano Maria Cecilia· Group Pres., ITT & Pharma. | Award | 23,742 | $0.00 | $0.00 | filing |
| 2026-02-27 | Rosenbloom David S.· EVP and General Counsel | Award | 26,709 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.